Skip To Main Content
Marie Bartenschlager on Muck Rack

Marie Bartenschlager

As seen in: Wiley Online Library, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marie

Contact Marie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Durability of Humoral Responses after an Adapted SARS-CoV-2 mRNA Vaccine Dose in Hemodialysis Patients

|
By Louise Benning, Marie Bartenschlager, Heeyoung Kim, Christian Morath
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Live‐virus serum neutralization after bivalent SARS‐CoV‐2 mRNA vaccination in hemodialysis patients

|
By Louise Benning, Marie Bartenschlager, Heeyoung Kim, Florian Kälble
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT The authors have nothing to report. Supporting Information Filename Description jmv29303-sup-0001-Supplemental_data.docx14.5 KB Supporting information. REFERENCES 1, , . Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis. 2020; 75(3): 417-425. doi:10.1053/j.ajkd.2019.06.014 2, , , et al.
Open in Who Shared Issue with article?

Viruses | Free Full-Text | BA.1/BA.5 Immunogenicity, Reactogenicity, and Disease Activity after COVID-19 Vaccination in Patients with ANCA-Associated Vasculitis: A Prospective Observational Cohort Study

|
By Claudius Speer, Maximilian Töllner, Louise Benning, Marie Bartenschlager
| MDPI
3. Results 3.1. Study Population and Baseline Characteristics We prospectively enrolled 64 AAV patients and 24 age- and vaccine-matched healthy controls before SARS-CoV-2 vaccination. Homologous or heterologous standard two-dose vaccination with mRNA (BNT162b2, BioNTech or mRNA-1273, Moderna) or adenovirus-vectored (ChAdOx1, AstraZeneca) vaccines were performed in all subjects and humoral responses as well as reactogenicity and AAV disease activity were assessed.
Open in Who Shared Issue with article?
See all 5 articles